文献速递妇科肿瘤

超灵敏循环肿瘤DNA检测与追踪预测局部晚期宫颈癌复发和生存:III期CALLA试验分析

Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses.
PubMed 文献 · Ann Oncol · 2025-06-02

CALLA试验中,局部晚期宫颈癌患者接受放化疗联合或不联合度伐利尤单抗治疗,采用超灵敏肿瘤知情检测法分析循环肿瘤DNA(ctDNA)和循环人乳头瘤病毒DNA。基线ctDNA检出率98.9%,ctDNA水平可预测疾病进展和生存,C3D1时ctDNA检出较临床进展中位提前164天。

要点

  • 基线ctDNA检出率98.9%(183/185),两治疗组间无差异。
  • 基线ctDNA低于中位数 vs 高于中位数:度伐利尤单抗+放化疗组无进展生存HR 0.61(0.28-1.35),总生存HR 0.55(0.23-1.35)。
  • C3D1时ctDNA检出较临床进展中位提前164天(95%CI 85-250)。

核心结论

  • 超灵敏ctDNA检测可作为局部晚期宫颈癌疾病进展和总生存的预测及预后标志物,且不依赖于疾病分期。

研究设计与样本

  • 全球随机III期CALLA试验(NCT03830866)分析,入组成年女性局部晚期宫颈癌患者(IB2-IIB期淋巴结阳性或IIIA-IVA期任何淋巴结状态),1:1随机接受度伐利尤单抗+放化疗或单纯放化疗。
  • 采用NeXT Personal®(Personalis)超灵敏肿瘤知情检测法,最多追踪1800个患者特异性变异,在基线、第3周期第1天(C3D1,放化疗后)和第6周期第1天(C6D1,放化疗后3个月)分析ctDNA和cHPV DNA。

主要发现

  • 基线ctDNA检出率为98.9%(183/185),两治疗组间无差异。
  • 基线ctDNA低于中位数 vs 高于中位数:度伐利尤单抗+放化疗组无进展生存HR 0.61(95%CI 0.28-1.35),总生存HR 0.55(95%CI 0.23-1.35);单纯放化疗组无进展生存HR 0.49(95%CI 0.26-0.95),总生存HR 0.65(95%CI 0.33-1.28)。
  • 治疗后ctDNA变化趋势与基线相似,且不依赖于分期或淋巴结状态。
  • C3D1时ctDNA检出较临床进展中位提前164天(95%CI 85-250)。
  • 基线cHPV DNA水平两治疗组间相似,但仅在治疗后具有预测性。

关键数值与推荐

  • 基线ctDNA低于中位数 vs 高于中位数:度伐利尤单抗+放化疗组无进展生存HR 0.61(95%CI 0.28-1.35),总生存HR 0.55(95%CI 0.23-1.35)。
  • 基线ctDNA低于中位数 vs 高于中位数:单纯放化疗组无进展生存HR 0.49(95%CI 0.26-0.95),总生存HR 0.65(95%CI 0.33-1.28)。
  • C3D1时ctDNA检出较临床进展中位提前164天(95%CI 85-250)。
  • 基线ctDNA检出率98.9%(183/185)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: After chemoradiotherapy (CRT), 30%-50% of patients with locally advanced cervical cancer (LACC) relapse, highlighting the unmet need for prognostic biomarkers. In the global randomized CALLA trial (NCT03830866), the addition of durvalumab during and after CRT did not significantly improve progression-free survival (PFS) in a biomarker-unselected intent-to-treat population. We analyzed the association of ultrasensitive circulating tumor DNA (ctDNA) and circulating human papillomavirus (cHPV) DNA detection with relapse and survival in the largest dataset in LACC to date. PATIENTS AND METHODS: In CALLA, adult women with stage IB2-IIB node-positive or IIIA-IVA any node-status LACC were randomized 1 : 1 to receive durvalumab + CRT or CRT alone. The NeXT Personal® (Personalis) ultrasensitive tumor-informed assay with up to 1800 patient-specific variants was used for ctDNA and cHPV DNA analysis at baseline, cycle 3 day 1 (C3D1, post-CRT), and C6D1 (3 months post-CRT). Correlations were analyzed between ctDNA/cHPV DNA detection and outcomes [PFS, overall survival (OS)]. RESULTS: ctDNA was detected in 98.9% (183/185) of baseline samples, with no difference between treatment arms. Detection levels of ctDNA were predictive of disease progression and survival at baseline: hazard ratios (95% confidence intervals) comparing PFS and OS, respectively, in the ctDNA less than median versus ctDNA greater than median subgroups were 0.61 (0.28-1.35) and 0.55 (0.23-1.35) with durvalumab + CRT, and 0.49 (0.26-0.95) and 0.65 (0.33-1.28) with CRT. Post-treatment trends were similar and independent of stage or lymph node status. ctDNA detection at C3D1 occurred a median of 164 days (95% confidence interval 85-250) days before clinical progression. Baseline cHPV DNA levels were similar but were only predictive following treatment. CONCLUSIONS: This study demonstrates the potential utility of ultrasensitive detection of ctDNA as a predictive and prognostic marker of disease progression and OS in LACC independent of disease stage.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Mayadev J, Vázquez Limón JC, Ramírez Godinez FJ, et al. Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses. Ann Oncol. 2025. PMID: 40500687. doi:10.1016/j.annonc.2025.05.533

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。